255 related articles for article (PubMed ID: 27258253)
1. Targeting DNA Damage Response in the Radio(Chemo)therapy of Non-Small Cell Lung Cancer.
Li L; Zhu T; Gao YF; Zheng W; Wang CJ; Xiao L; Huang MS; Yin JY; Zhou HH; Liu ZQ
Int J Mol Sci; 2016 May; 17(6):. PubMed ID: 27258253
[TBL] [Abstract][Full Text] [Related]
2. Influence of DNA repair gene polymorphisms on prognosis in inoperable non-small cell lung cancer patients treated with radiotherapy and platinum-based chemotherapy.
Butkiewicz D; Drosik A; Suwiński R; Krześniak M; Rusin M; Kosarewicz A; Rachtan J; Matuszczyk I; Gawkowska-Suwińska M
Int J Cancer; 2012 Oct; 131(7):E1100-8. PubMed ID: 22511383
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer.
Su D; Ma S; Liu P; Jiang Z; Lv W; Zhang Y; Deng Q; Smith S; Yu H
Lung Cancer; 2007 May; 56(2):281-8. PubMed ID: 17222938
[TBL] [Abstract][Full Text] [Related]
4. The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer.
Zhao J; Fu W; Liao H; Dai L; Jiang Z; Pan Y; Huang H; Mo Y; Li S; Yang G; Yin J
BMC Cancer; 2015 Oct; 15():731. PubMed ID: 26482648
[TBL] [Abstract][Full Text] [Related]
5. DNA repair and cytotoxic drugs: the potential role of RAD51 in clinical outcome of non-small-cell lung cancer patients.
Nogueira A; Assis J; Catarino R; Medeiros R
Pharmacogenomics; 2013 Apr; 14(6):689-700. PubMed ID: 23570471
[TBL] [Abstract][Full Text] [Related]
6. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
Gurubhagavatula S; Liu G; Park S; Zhou W; Su L; Wain JC; Lynch TJ; Neuberg DS; Christiani DC
J Clin Oncol; 2004 Jul; 22(13):2594-601. PubMed ID: 15173214
[TBL] [Abstract][Full Text] [Related]
7. MicroRNAs associated with therapy of non-small cell lung cancer.
Lu J; Zhan Y; Feng J; Luo J; Fan S
Int J Biol Sci; 2018; 14(4):390-397. PubMed ID: 29725260
[TBL] [Abstract][Full Text] [Related]
8. Role of XRCC1 gene polymorphisms in non-small cell lung cancer cisplatin-based chemotherapy, and their effect on clinical and pathological characteristics.
Liu HF; Liu JS; Deng JH; Wu RR
Genet Mol Res; 2016 Dec; 15(4):. PubMed ID: 28081275
[TBL] [Abstract][Full Text] [Related]
9. Functional promoter rs2868371 variant of HSPB1 associates with radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with radio(chemo)therapy.
Lopez Guerra JL; Wei Q; Yuan X; Gomez D; Liu Z; Zhuang Y; Yin M; Li M; Wang LE; Cox JD; Liao Z
Radiother Oncol; 2011 Nov; 101(2):271-7. PubMed ID: 21937138
[TBL] [Abstract][Full Text] [Related]
10. [Neoadjuvant chemo (chemoradio) therapy for advanced non-small cell lung cancer].
Yokomise H
Nihon Geka Gakkai Zasshi; 2014 May; 115(3):120-4. PubMed ID: 24946517
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
[TBL] [Abstract][Full Text] [Related]
12. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.
Felip E; Rosell R
Expert Rev Mol Diagn; 2007 May; 7(3):261-8. PubMed ID: 17489733
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
Sullivan I; Salazar J; Majem M; Pallarés C; Del Río E; Páez D; Baiget M; Barnadas A
Cancer Lett; 2014 Oct; 353(2):160-6. PubMed ID: 25069034
[TBL] [Abstract][Full Text] [Related]
14. Decreased miRNA-148a is associated with lymph node metastasis and poor clinical outcomes and functions as a suppressor of tumor metastasis in non-small cell lung cancer.
Chen Y; Min L; Zhang X; Hu S; Wang B; Liu W; Wang R; Gu X; Shen W; Lv H; Zou J; Chen Y; Xu X; Chen L
Oncol Rep; 2013 Oct; 30(4):1832-40. PubMed ID: 23843100
[TBL] [Abstract][Full Text] [Related]
15. 3'-Phosphoadenosine 5'-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents.
Leung AW; Dragowska WH; Ricaurte D; Kwok B; Mathew V; Roosendaal J; Ahluwalia A; Warburton C; Laskin JJ; Stirling PC; Qadir MA; Bally MB
Oncotarget; 2015 Jul; 6(19):17161-77. PubMed ID: 26220590
[TBL] [Abstract][Full Text] [Related]
16. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
17. [Which treatments should be proposed in resectable stage III cancers?].
Thibout Y; Cortot A; Chapet O; Mornex F; Milleron B
Rev Pneumol Clin; 2004 Nov; 60(5 Pt 2):3S37-42. PubMed ID: 15536351
[TBL] [Abstract][Full Text] [Related]
18. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT.
Tièche CC; Peng RW; Dorn P; Froment L; Schmid RA; Marti TM
BMC Cancer; 2016 Feb; 16():125. PubMed ID: 26895954
[TBL] [Abstract][Full Text] [Related]
19. The evolving locally-advanced non-small cell lung cancer landscape: Building on past evidence and experience.
Méry B; Guy JB; Swalduz A; Vallard A; Guibert C; Almokhles H; Ben Mrad M; Rivoirard R; Falk AT; Fournel P; Magné N
Crit Rev Oncol Hematol; 2015 Nov; 96(2):319-27. PubMed ID: 26095618
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemoradiotherapy followed by surgery for stage IIIa and IIIb non-small-cell lung cancer (NSCLC): is it still justified?
Mirimanoff RO
Chin Clin Oncol; 2015 Dec; 4(4):49. PubMed ID: 26730761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
